Search results
Jun 10, 2024 · The FDA has advised manufacturers to update COVID-19 vaccines to target the JN.1 variant. KP.2 and KP.3, offshoots of JN.1, are now the dominant variants in circulation. If the FDA signs off on the decision and the CDC makes a recommendation, the booster shot will be available in the fall.
- Fran Kritz
Jun 20, 2024 · The drug, developed by Pfizer, had an 89% reduction in the risk of hospitalization and death in unvaccinated people in the clinical trial that supported the EUA, a number that was high enough to prompt the National Institutes of Health (NIH) to prioritize it over other COVID treatments.
- kathy.katella-cofrancesco@yale.edu
6 days ago · People 18 years of age and older can receive a booster dose with any available mRNA COVID-19 vaccine as to date, there has not been a difference between Pfizer and Moderna in terms of the risk of myocarditis and/or pericarditis following booster doses.
Jun 24, 2024 · The FDA has issued an updated recommendation advising vaccine manufacturers to make COVID-19 booster targeting the KP.2 strain.
6 days ago · Following a second bivalent booster, many SOTRs regained the ability to neutralize both virus strains; yet 42% did not have any detectable immunity to XBB.1.5. ... The work was supported by ...
6 days ago · Research finds that booster doses of bivalent vaccines given every three to six months helps maintain a person's ability to neutralize multiple SARS-CoV-2 strains, including XBB.1.5 People who ...
Jun 28, 2024 · COVID Vaccines Advised for Fall Will Include a Newer Option: Novavax. This rival to Moderna and Pfizer uses a more traditional vaccine technology. Novavax utilizes proteins rather than messenger ...
